MedTrace Logo

Functional Imaging to Identify Radiosensitive Esophageal Cancer - a Biomarker Validation Study

NCT06189898 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 48

Last updated 2024-01-05

No results posted yet for this study

Summary

This trial on biomarker validation investigates the use of innovative re-staging FDG-PET parameters to detect highly chemoradiation (CRT) sensitive squamous cell carcinomas of the esophagus (SCEC) at the end of preoperative or definitive CRT.

Conditions

  • Esophagus Cancer

Interventions

DIAGNOSTIC_TEST

Re Staging FDG-PET

Additional interim FDG-PET during week four of preoperative or definitive chemoradiation for esophageal carcinomas. Evaluation of standardized uptake ratio (SUR) and increased uptake of non tumor affected esophagus (Delta NTO).

Sponsors & Collaborators

  • Helmholtz Zentrum Dresden Rossendorf, Dresden, Germany

    collaborator UNKNOWN

  • Sebastian Zschaeck

    lead OTHER

Principal Investigators

  • Sebastian Zschaeck, MD · Charite University, Berlin, Germany

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-15
Primary Completion
2029-01-31
Completion
2029-01-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06189898 on ClinicalTrials.gov